APRT
APRT (adenine phosphoribosyltransferase) is a cytoplasmic enzyme of the purine salvage pathway. It catalyses the formation of AMP from adenine and 5-phosphoribosyl-1-pyrophosphate, a route that costs the cell less energy than de novo synthesis. Browse Assay Genie's current range of APRT research reagents below, or read on for the biology behind the target.
APRT catalyses a salvage reaction that results in the formation of AMP. Specifically, the enzyme converts adenine and 5-phosphoribosyl-1-pyrophosphate (PRPP) into AMP and inorganic pyrophosphate. UniProt notes that this salvage route is energetically less costly than de novo synthesis, so it lets cells recycle free adenine instead of building nucleotides from scratch. APRT also handles adenine that is produced as a by-product of the polyamine biosynthesis pathway.
The APRT gene encodes a protein that belongs to the purine/pyrimidine phosphoribosyltransferase family and sits within the HGNC gene group of phosphoribosyltransferases. UniProt lists its subcellular location as the cytoplasm. NCBI Gene describes a conserved distribution of CpG dinucleotides across the gene, and reports two transcript variants that encode different isoforms. Mouse and rat both carry an orthologous gene, Aprt, which allows the enzyme to be studied in rodent models.
APRT is best known clinically through its deficiency. A homozygous deficiency of the enzyme causes 2,8-dihydroxyadenine urolithiasis, a kidney stone disorder, which makes the protein a reference point for work on purine metabolism and inherited metabolic disease. Researchers studying APRT activity, expression or the wider purine salvage network can use an APRT antibody, an APRT ELISA kit or recombinant APRT protein to support their work.
APRT forms AMP from adenine and PRPP, a salvage route that is energetically less costly than de novo synthesis.
The enzyme deals with adenine produced as a by-product of the polyamine biosynthesis pathway, linking the two pathways.
Homozygous APRT deficiency causes 2,8-dihydroxyadenine urolithiasis, so the enzyme is central to studies of this kidney stone disorder.
The APRT gene has a conserved CpG dinucleotide distribution and two transcript variants that encode different isoforms.
APRT catalyses the formation of AMP and inorganic pyrophosphate from adenine and 5-phosphoribosyl-1-pyrophosphate. This salvage reaction is energetically less costly than de novo synthesis. The enzyme also deals with adenine generated as a by-product of polyamine biosynthesis.
NCBI Gene reports two transcript variants of the APRT gene that encode different isoforms. The HGNC full name is adenine phosphoribosyltransferase, and no alternative symbols or previous names are listed. The enzyme carries the EC number 2.4.2.7.
A homozygous deficiency in APRT causes 2,8-dihydroxyadenine urolithiasis. The gene has orthologues named Aprt in mouse and rat. Check the datasheet of any product for its validated reactivity.
Other purine metabolism enzymes and phosphoribosyltransferases that work alongside APRT in nucleotide salvage.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P07741; product specifications from Assay Genie datasheets.